New hope for MS patients: can a drug switch stop symptom comebacks?
NCT ID NCT07389590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether switching from ocrelizumab to ublituximab can reduce or delay the return of MS symptoms that some patients experience before their next scheduled infusion. Researchers will enroll 50 adults with relapsing MS who have been on ocrelizumab for at least a year and report this 'wearing-off' phenomenon. Participants will be monitored for changes in symptom severity and quality of life over several infusion cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ublituximab
What this could lead to
If it works, this could offer a new option for people with MS whose symptoms return before their next infusion, improving their quality of life.
What could go wrong
This is a small pilot study, so results may not apply to everyone. The benefit may be small or not seen at all, and switching drugs carries its own risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States